Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAlfonso Galderisi, MD, PhD
he/him/his
Associate Professor AdjunctAbout
Research
Publications
2025
Automated Oral Minimal Models for Rapid Estimation of Insulin Sensitivity and Beta-Cell Responsivity in Large-Scale Data Sets: A Validation Study.
Perazzolo S, Galderisi A, Carr A, Dayan C, Cobelli C. Automated Oral Minimal Models for Rapid Estimation of Insulin Sensitivity and Beta-Cell Responsivity in Large-Scale Data Sets: A Validation Study. Journal Of Diabetes Science And Technology 2025, 19322968251365274. PMID: 40899768, PMCID: PMC12408534, DOI: 10.1177/19322968251365274.Peer-Reviewed Original ResearchNovel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.
Sims E, Russell W, Cuthbertson D, Skyler J, Jacobsen L, Ismail H, Redondo M, Nathan B, Carr A, Taylor P, Dayan C, Galderisi A, Herold K, Sosenko J. Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes 2025 PMID: 40877213, DOI: 10.2337/db25-0310.Peer-Reviewed Original Research18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance
GALDERISI A, MARCHIORI H, ALGUARD M, DESOUSA M, TICHY E, FLYNN A, GAGLIA J, DALLA MAN C, SHERR J. 18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance. Diabetes 2025, 74 DOI: 10.2337/db25-18-or.Peer-Reviewed Original ResearchOral glucose tolerance testNormal glucose toleranceInsulin secretion rateGlucose tolerance testIncretin effectStage 0GLP-1Islet autoantibodiesTolerance testGlucose tolerancePreclinical type 1 diabetesStage 1Reduced incretin effectHormone GLP-1Iv glucose tolerance testType 1 diabetesMultiple islet autoantibodiesPhenotype of peopleOral minimal modelC-peptideMetabolic phenotypeGlucose profilesIncretinMeasurement of glucoseInsulin secretion1962-LB: Baseline Insulin Secretion Determines the Response to Abatacept In Stage 1 Type 1 Diabetes
CARR A, GALDERISI A, TAYLOR P, BONET J, CUTHBERTSON D, SOSENKO J, SIMS E, EVANS-MOLINA C, DALLA MAN C, SENIOR P, ISMAIL H, NATHAN B, PETRELLI A, SHERR J, HEROLD K, RUSSELL W, MORAN A, DAYAN C. 1962-LB: Baseline Insulin Secretion Determines the Response to Abatacept In Stage 1 Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1962-lb.Peer-Reviewed Original ResearchOral minimal modelHigh secretorsEunice Kennedy Shriver National Institute of Child HealthOral glucose tolerance testAge-adjusted ANCOVACTLA-4-immunoglobulinInsulin secretionNational Institute of AllergyImmune Tolerance NetworkRisk regression analysisNational Center for Research ResourcesNational Institute of Child HealthGlucose tolerance testInstitute of Child HealthDelay disease progressionInstitute of AllergyNational Institute of DiabetesCanadian Institutes of Health ResearchBaseline insulin secretionDigestive and Kidney DiseasesBeta cell functionQuantify insulin secretionBeta cell responses to glucoseCell response to glucoseAbatacept arms1360-P: CGM Sensors Improve the Estimation of Glycemic Outcomes in Newborns at Risk of Neonatal Hypoglycemia
MONTHE-DREZE C, CHERKERZIAN S, PRENDIN F, COBURN-SANDERSON A, ABDEL-RAHMAN R, DELFAVERO S, GALDERISI A, FACCHINETTI A, SEN S. 1360-P: CGM Sensors Improve the Estimation of Glycemic Outcomes in Newborns at Risk of Neonatal Hypoglycemia. Diabetes 2025, 74 DOI: 10.2337/db25-1360-p.Peer-Reviewed Original ResearchNeonatal hypoglycemiaContinuous glucose monitoringRisk of neonatal hypoglycemiaPoint-of-careGlycemic outcomesManagement of NHWeeks gestational ageImprove neurodevelopmental outcomesCapillary point-of-careCompared glycemic outcomesBlinded continuous glucose monitoringPoint-of-care methodWilcoxon Signed Rank TestMcNemar chi2Gestational ageContinuous glucose monitoring tracesNeurodevelopmental outcomesDetection rateAdverse neurodevelopmentNeonatesMedical managementBlood glucoseContinuous glucose monitoring inaccuracyRank testNewborns230-OR: A Real-Time Recalibration Algorithm to Improve the Accuracy of CGM Sensors in Newborns
PRENDIN F, DELFAVERO S, CHERKERZIAN S, COBURN-SANDERSON A, ABDEL-RAHMAN R, MONTHE-DREZE C, GALDERISI A, SEN S, FACCHINETTI A. 230-OR: A Real-Time Recalibration Algorithm to Improve the Accuracy of CGM Sensors in Newborns. Diabetes 2025, 74 DOI: 10.2337/db25-230-or.Peer-Reviewed Original ResearchNeonatal hypoglycemiaContinuous glucose monitoringLong-term neurodevelopmental sequelaeMean absolute relative differenceNeonatal blood glucoseBlood glucoseNon-diabetic controlsIRB-approved studyNeurodevelopmental sequelaeThird trimesterStatistically significant improvementPhysiology of neonatesPregnant womenCGM sensorsReal-time recalibrationNewbornsContinuous glucose monitoring sensorContinuous glucose monitoring dataStandard careReal-timeSensor accuracyAccuracy of continuous glucose monitoringAlgorithmRecalibration algorithmDexcom G6 sensor719-P: Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials—Evidence from Stage 1 and Stage 2 Trials
GALDERISI A, CUTHBERTSON D, PETRELLI A, MORAN A, SOSENKO J, JACOBSEN L, LIBMAN I, REDONDO M, ISMAIL H. 719-P: Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials—Evidence from Stage 1 and Stage 2 Trials. Diabetes 2025, 74 DOI: 10.2337/db25-719-p.Peer-Reviewed Original ResearchOral disposition indexC-peptide indexAUC C-peptideC-peptideMarkers of treatment effectivenessStage 1B cell functionYear of treatmentC-peptide measurementsType 1 diabetesPlacebo armMeasure of B-cell functionStage 2T1D prevention trialsTreatment responseTreated armClinical trialsDisposition indexSensitive markerPrevention trialsMetabolic endpointsLong-term effectsInsulin secretionOutcome measuresTeplizumabWS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study
Bonnel A, Galderisi A, Weiss L, Sermet-Gaudelus I, Besancon A, Letierce A, Sahki D, Group M. WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study. Journal Of Cystic Fibrosis 2025, 24: s33. DOI: 10.1016/j.jcf.2025.03.586.Peer-Reviewed Original ResearchOral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceCF-related diabetesBaseline oral glucose tolerance testAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsOGTT glucoseBMI z-scoreYear of treatmentImpaired fasting glucoseImpaired glucose toleranceGlucose tolerance testForced expiratory volumeCFTR modulatorsPulmonary infectionDecrease recurrenceBaseline characteristicsRelated diabetesFasting GlucoseTolerance testInsulin treatmentReal-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same?
Zanfardino A, Ippolito G, Ozen G, Galderisi A, Rollato A, Chianese A, Testa V, del Giudice E, Scaramuzza A, Iafusco D. Real-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same? Diabetes Technology & Therapeutics 2025, 27: 669-673. PMID: 40170658, DOI: 10.1089/dia.2025.0106.Peer-Reviewed Original ResearchHigh-carbohydrate mealInsulin deliveryPostprandial blood glucose levelsType 1 diabetesControl-IQBlood glucose levelsPostprandial glycemic responseNo significant differenceBolus strategyGlycemic controlGlucose levelsAutomated Insulin DeliverySignificant differenceBolusGlycemic responseInsulin bolusMiniMed 780GCorrection bolusesTarget rangeHigh-carbohydratePizza consumptionDelivery systemInsulin delivery systemsThe Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
Ismail H, Cuthbertson D, Galderisi A, Libman I, Jacobsen L, Moran A, Petrelli A, Atkinson M, Redondo M, Hannon T, Mather K, Sosenko J. The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. Diabetes 2025, 74: 1196-1204. PMID: 40173211, PMCID: PMC12185960, DOI: 10.2337/db24-1000.Peer-Reviewed Original ResearchConceptsFirst-phase insulin responseArea under the curveArea under the curve ratioType 1 diabetesB cell functionAutoantibody-positive individualsDPT-1Glucose tolerance testMatsuda indexDisposition indexRegression modelsDiabetic rangeAnalyzed cross-sectionallyTolerance testDiabetes Prevention Trial-Type 1Oral glucose tolerance testProgression to type 1 diabetesStudy participantsCox regression modelsAntibody-positive relativesInsulin secretionPrediction of T1DRisk scoreIntravenous glucose tolerance testMeasure of B-cell function
Academic Achievements & Community Involvement
News
News
- November 25, 2025
Alfonso Galderisi, MD, PhD: What to Know During Diabetes Awareness Month
- October 08, 2025Source: Science Press Releases
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
- February 28, 2024
Find Yale Pediatrics at the 2024 Pediatric Academic Societies (PAS) Meeting